BFM
KPTI icon

Boothbay Fund Management’s Karyopharm Therapeutics KPTI Stock Holding History

Boothbay Fund Management’s Portfolio KPTI Stock Details KPTI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$1.19M Buy
213,810
+69,182
+48% +$527K 0.02% 860
2025
Q4 		$1.06M Buy
+144,628
New +$885K 0.02% 774
2025
Q1 		– Sell
-6,042
Closed -$61.3K – 1596
2024
Q4 		$61.3K Sell
6,042
-31
-0.5% -$375 ﹤0.01% 1334
2024
Q3 		$75.6K Hold
6,073
– – ﹤0.01% 1479
2024
Q2 		$79K Hold
6,073
– – ﹤0.01% 1369
2024
Q1 		$138K Buy
6,073
+624
+11% +$10.9K ﹤0.01% 1383
2023
Q4 		$70.7K Hold
5,449
– – ﹤0.01% 1485
2023
Q3 		$110K Hold
5,449
– – ﹤0.01% 1552
2023
Q2 		$146K Buy
5,449
+1,355
+33% +$58.4K ﹤0.01% 1550
2023
Q1 		$239K Buy
+4,094
New +$202K ﹤0.01% 1642
2021
Q4 		– Sell
-2,641
Closed -$231K – 2055
2021
Q3 		$231K Buy
2,641
+1,103
+72% +$114K 0.01% 1491
2021
Q2 		$238K Buy
+1,538
New +$223K 0.01% 1415
2019
Q3 		– Sell
-2,455
Closed -$333K – 839
2019
Q2 		$221K Sell
2,455
-9,569
-80% -$768K 0.02% 597
2019
Q1 		$1.05M Buy
+12,024
New +$1.33M 0.1% 219
2018
Q3 		– Sell
-1,360
Closed -$347K – 870
2018
Q2 		$347K Buy
+1,360
New +$336K 0.03% 436

Other funds holding KPTI

CC
Commodore Capital New York $1.73B AUM 298.96% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
APM
Avidity Partners Management Dallas, Texas $936M AUM 195% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
CCM
Catalio Capital Management New York $479M AUM 140.7% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
IC
Ikarian Capital Dallas, Texas $1.23B AUM 600.17% 1-Year Est. Return
AAA
Affinity Asset Advisors New York $1.94B AUM 374.45% 1-Year Est. Return

Boothbay Fund Management's KPTI Position: Q1 2026 in Review

Boothbay Fund Management increased its Karyopharm Therapeutics (KPTI) stake by 48% in Q1 2026, buying an estimated $527K and bringing the position to 213,810 shares worth $1.19M. The position accounts for 0.02% of the portfolio, ranked #860.

Boothbay Fund Management first reported a position in KPTI in Q2 2018 and has held it in 15 quarters since. 77 funds tracked by Wall St. Rank hold KPTI as of Q1 2026.

  • Boothbay Fund Management held 213,810 shares of Karyopharm Therapeutics worth $1.19M as of Q1 2026.
  • Boothbay Fund Management bought 69,182 Karyopharm Therapeutics shares in Q1 2026, an estimated $527K.
  • Karyopharm Therapeutics made up 0.02% of Boothbay Fund Management's portfolio in Q1 2026, its #860 holding.
  • Boothbay Fund Management first reported a position in Karyopharm Therapeutics in Q2 2018 and has held it in 15 quarters since.
  • 77 funds tracked by Wall St. Rank held Karyopharm Therapeutics as of Q1 2026.

Based on Boothbay Fund Management's 13F filing for Q1 2026, filed 15 May 2026.